Team
Portfolio
Contact
News
Sixth Element Capital welcomes the successful IPO of Nuvectis on Nasdaq
8th February, 2022
Sixth Element Capital welcomes Nuvectis’s initiation of the Phase I clinical trial of NXP800
4th January, 2022
Sixth Element Capital announces licence agreement with Nuvectis Inc on the HSF1 Programme
26th August, 2021
Sixth Element Capital welcomes Achilles Therapeutic’s announcement of its NASDAQ IPO
30th March, 2021
Sixth Element Capital welcomes NeoPhore Therapeutic’s announcement of its £15.2m Series B financing
9th March, 2021
Sixth Element Capital welcomes Achilles Therapeutic’s announcement of its £52.7m Series C financing
19th November, 2020
Sixth Element Capital welcomes Azeria Therapeutic’s announcement of its £32m Series B financing
21st November, 2019
Sixth Element Capital and Cancer Research UK Beatson Institute Announce Major Collaboration to Develop Novel RAS Inhibitors with Novartis
24th October, 2019
Sixth Element Capital welcomes Achilles Therapeutic’s announcement of its £100m Series B financing
3rd September, 2019
Sixth Element Capital announces licence agreement with Stemline Therapeutics on the RET Inhibitor Programme
11th March, 2019
Sixth Element Capital welcomes AdoRx Therapeutics Collaboration with Johnson and Johnson
28th February, 2019
Azeria Therapeutics announces Series A investment from Sixth Element Capital
4th September, 2018
AdoRx Therapeutics announces initial funding of $10 million for the discovery of new cancer therapeutics
21st June, 2018
Sixth Element Capital welcomes NeoPhore’s announcement of a £1m BioMedical Catalyst grant by Innovate UK
16th April, 2018
Sixth Element Capital welcomes Macrophage Pharma’s announcement of the appointment of Michael Moore as Chairman
11th April, 2018
Sixth Element Capital welcomes NeoPhore’s announcement of the appointment of Jeffrey Roix as Chief Executive Officer
11th April, 2018
Sixth Element Capital welcomes Sierra Oncology’s update on SRA737
1st March, 2018
Sixth Element Capital welcome the formation of NeoPhore’s Scientific Advisory Board
8th January, 2018
Sixth Element Capital welcomes Boston Pharmaceutical’s portfolio update including MPS1
5th January, 2018
NeoPhore scientific founders publish breakthrough immuno-oncology discoveries in Nature
29th November, 2017
PhoreMost and Sixth Element Capital announce creation and investment in NeoPhore, an immuno-oncology company
15th November, 2017
Sixth Element Capital welcomes Macrophage Pharma Limited’s announcement to Extend Series A Round to Include New Investor Merck Ventures
23rd August, 2017
CRT Pioneer Fund, Cancer Research UK and NCI collaborate to boost research against the ‘undruggable’ RAS
19th April, 2017
CRT Pioneer Fund and Cardiff University Announce the Initiation of the Phase II MONOCLE Study of Tefinostat
8th February, 2017
CRT Pioneer Fund and Cancer Research UK’s Manchester Institute nominate cancer drug candidate
20th January, 2017
Macrophage Pharma raises £9 million in Series A financing and acquires immune-oncology technology platform
9th January, 2017
CRT Pioneer Fund Announces Transfer of Sponsorship of SRA737 Clinical Trials
9th January, 2017
CRT Pioneer Fund announces investment in blood cancer drugs
8th December, 2016
Sixth Element Capital welcomes BACIT Ltd’s announcement to create £1 billion life science investment champion
7th November, 2016
Achilles Therapeutics launched with funds of £13.2 million to develop immunotherapies for cancer
5th October, 2016
ProNAi licenses oncology drug targeting DNA damage response checkpoint kinase 1 (chk1) from CRT Pioneer Fund, UK
27th September, 2016
Artios Pharma Company launch and fundraising of $33.2 miilion to focus on novel DNA damage response cancer therapies
21st September, 2016
CRT Pioneer Fund boosts investment in drugs that block cancer defences
5th May, 2016
CRT Pioneer Fund banks £20m investment from BACIT and expands agreement with Chroma Therapeutics to develop cancer immunotherapies
16th December, 2014
£50m CRT Pioneer Fund announces investment to develop lung cancer drugs at Cancer Research UK’s Manchester Institute
21st November, 2014
CRT Pioneer Fund collaborates with Chroma Therapeutics to develop cancer drugs targeting the immune system
31st October, 2013
CRT Pioneer Fund, BACIT and Sareum enter agreement to fund development of drugs to treat cancers including pancreatic, bowel and lung
24th September, 2013
The £50m CRT Pioneer Fund announces first investment to develop cancer drugs
23rd April, 2013
CRT and the EIF unveil innovative £50m cancer fund to bridge ‘development gap’ in UK
29th March, 2012